With Pfizer deal, Global Blood CEO sees opportunity to reach sickle cell patients globally

The $5.4 billion acquisition of Global Blood Therapeutics by Pfizer was sealed with a phone call and a commitment to reach patients with sickle cell disease wherever in the world they live.

“When Albert called me, the first thing he said was, ‘You guys have really been amazing in what you’ve done in such a short period of time,’” said Ted Love, Global Blood’s CEO, recalling for me his conversation with Pfizer CEO Albert Bourla.

Then came Bourla’s pitch. “He told me Pfizer was excited to deploy its resources and global footprint to address all the patients,” Love said.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In